Search
Now showing items 1-2 of 2
Influence of the UGT2B17 Gene on the Relationship Between Exemestane and Bone Mineral Density in Postmenopausal Women
Background: In the Mammary Prevention.3 (MAP.3) randomized placebo-controlled trial of exemestane, postmenopausal women experienced a loss in bone mineral density (BMD). UGT2B17 facilitates excretion of androgens and ...
The Association between the UGT2B17 Gene Deletion and Menopause-Related Quality of Life in Postmenopausal Women in the CCTG MAP.3 Breast Cancer Chemoprevention Trial
Background: Mammary Prevention.3 (MAP.3) was a randomized placebo controlled trial of exemestane for breast cancer prevention. Participants commonly experienced vasomotor symptoms, such as hot flashes. Exemestane is ...